Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc (LSE/NYSE: HLN) covers the month of May 2025, with a specific reporting date of May 13, 2025. The document serves as a notification and public disclosure under the UK Market Abuse Regulation regarding transactions by Persons Discharging Managerial Responsibilities (PDMRs). Haleon operates as a global leader in consumer health with a portfolio spanning Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report is strictly a regulatory disclosure of a specific share transaction and does not contain financial performance data.
Material Changes
The material change disclosed is a share purchase transaction by an Independent Non-Executive Director. On May 9, 2025, Marie-Anne Aymerich purchased 21,300 ordinary shares of Haleon Plc at a price of £4.051 per share on the London Stock Exchange (XLON). No other material changes to the company's operations or financial position are detailed in this document.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or a discussion of risks and contingencies. The document is limited to the statutory disclosure of the PDMR transaction.
Key Facts for Investor Verification
- Transaction Date: May 9, 2025.
- Transacting Party: Marie-Anne Aymerich, Independent Non-Executive Director.
- Transaction Type: Purchase of Ordinary Shares.
- Volume: 21,300 shares.
- Price: £4.051 per share.
- Exchange: London Stock Exchange (XLON).
- Financial Data: No financial performance data is included in this filing.